gross profit bridgeinconsistent2016-12-31
Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.
Revenue
$1.39B
Fiscal year ended 2025-12-31Operating income
$199.39M
Fiscal year ended 2025-12-31Free cash flow
$173.29M
Fiscal year ended 2025-12-31LivaNova PLC (LIVN) reported revenue of $1.39B and net income of -$242.47M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from LivaNova PLC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.39B | $1.25B | $1.15B | $1.02B | $1.04B | $934.24M | $1.08B | $1.11B | $1.01B | $964.86M |
| Cost of revenue | $448.18M | $399.95M | $397.72M | $314.58M | $329.37M | $339.48M | $360.36M | $361.32M | $353.19M | Unavailable |
| Gross profit | $939.87M | $853.48M | $755.82M | $707.23M | $705.99M | $594.76M | $723.80M | $745.64M | $651.62M | Unavailable |
| Operating income | $199.39M | $129.05M | -$68.50M | -$76.75M | -$784.00K | -$273.90M | -$171.55M | -$248.07M | $96.49M | $33.45M |
| Net income | -$242.47M | $63.23M | $17.55M | -$86.25M | -$135.82M | -$348.82M | -$157.64M | -$189.40M | -$25.09M | -$62.79M |
| Research & development | $185.76M | $182.51M | $193.82M | $155.80M | $183.41M | $152.90M | $146.85M | $145.95M | $109.52M | $82.08M |
| Weighted-average diluted shares | shares 54.55M | shares 54.57M | shares 54.21M | shares 53.47M | shares 50.63M | shares 48.59M | shares 48.35M | shares 48.50M | shares 48.50M | shares 49.01M |
| Pretax income | -$220.78M | $88.31M | -$81.23M | -$75.14M | -$124.47M | -$348.02M | -$188.38M | -$247.45M | $121.14M | $25.67M |
| Income tax expense | $21.64M | $25.06M | -$98.88M | $11.05M | $11.20M | -$960.00K | -$30.37M | -$69.63M | $49.95M | $5.11M |
| Diluted EPS | $-4.45 | $1.16 | $0.32 | $-1.61 | $-2.68 | $-7.18 | $-3.26 | $-3.91 | $-0.52 | $-1.28 |
| Selling, general & administrative | $548.81M | $508.88M | $502.70M | $469.24M | $471.90M | $446.56M | $528.47M | $464.97M | $380.10M | $355.16M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $635.55M | $428.86M | $266.50M | $214.17M | $207.99M | $252.83M | $61.14M | $47.20M | $93.62M | $39.79M |
| Total assets | $2.61B | $2.51B | $2.43B | $2.29B | $2.20B | $2.40B | $2.41B | $2.55B | $2.50B | $2.34B |
| Current assets | $1.10B | $1.13B | $988.16M | $886.14M | $679.18M | $708.04M | $549.44M | $533.30M | $869.86M | $812.69M |
| Total liabilities | $1.41B | $1.19B | $1.15B | $1.09B | $906.31M | $1.29B | $1.03B | $1.05B | $688.58M | $635.72M |
| Current liabilities | $808.07M | $392.12M | $334.98M | $297.40M | $696.97M | $309.05M | $512.55M | $496.75M | $406.02M | $349.89M |
| Total equity incl. NCI | $1.20B | $1.32B | $1.28B | $1.21B | $1.29B | $1.11B | $1.38B | $1.50B | $1.82B | $1.71B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $164.70M | $147.57M | $147.89M | $129.38M | $105.84M | $115.28M | $164.15M | $153.54M | $144.47M | $133.02M |
| Accounts receivable | $215.98M | $193.16M | $215.07M | $183.11M | $185.35M | $184.36M | $257.77M | $256.14M | $282.14M | $213.26M |
| Goodwill | $792.84M | $750.01M | $782.94M | $768.79M | $899.52M | $922.32M | $915.79M | $956.82M | $784.24M | $691.71M |
| Long-term debt | $345.18M | $549.62M | $568.54M | $518.07M | $9.85M | $642.30M | $260.33M | $139.54M | $61.96M | $75.22M |
| Accounts payable | $97.16M | $69.73M | $80.84M | $74.31M | $68.00M | $73.67M | $85.89M | $76.74M | $85.92M | $71.93M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $254.34M | $183.04M | $74.91M | $69.92M | $102.54M | -$79.42M | -$91.14M | $120.49M | $91.34M | $90.15M |
| Capital expenditures | $81.05M | $47.11M | $34.98M | $26.52M | $25.48M | $35.02M | $24.69M | $37.19M | $32.93M | $38.36M |
| Investing cash flow | -$72.91M | -$48.16M | -$40.33M | -$38.41M | $36.90M | -$41.84M | -$41.29M | -$120.56M | -$52.86M | -$44.52M |
| Financing cash flow | -$285.66M | $18.55M | $21.48M | $280.13M | -$181.48M | $310.76M | $146.58M | -$42.35M | $11.29M | -$118.04M |
| Net change in cash | -$88.00M | $145.68M | $62.25M | $307.63M | -$44.84M | $191.70M | $13.93M | -$46.41M | $53.83M | -$72.82M |
| Stock-based compensation | $36.29M | $33.93M | $36.35M | $44.81M | $40.56M | $35.09M | $32.55M | $26.92M | $19.06M | $19.57M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $0 | $0 | $50.00M | $0 | $54.49M |
| Depreciation & amortization | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $85.36M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $173.29M | $135.93M | $39.93M | $43.40M | $77.07M | -$114.45M | -$115.83M | $83.30M | $58.41M | $51.79M |
| Gross margin | 67.7% | 68.1% | 65.5% | 69.2% | 68.2% | 63.7% | 66.8% | 67.4% | Unavailable | Unavailable |
| Operating margin | 14.4% | 10.3% | -5.9% | -7.5% | -0.1% | -29.3% | -15.8% | -22.4% | 9.5% | 3.5% |
| FCF margin | 12.5% | 10.8% | 3.5% | 4.2% | 7.4% | -12.3% | -10.7% | 7.5% | 5.8% | 5.4% |
| SBC / revenue | 2.6% | 2.7% | 3.2% | 4.4% | 3.9% | 3.8% | 3.0% | 2.4% | 1.9% | 2.0% |
| Current ratio | 1.36x | 2.87x | 2.95x | 2.98x | 0.97x | 2.29x | 1.07x | 1.07x | 2.14x | 2.32x |
| Revenue YoY growth | 10.7% | 8.7% | 12.9% | -1.3% | 10.8% | -13.8% | -2.1% | 9.4% | 4.9% | Unavailable |
| Net margin | -17.5% | 5.0% | 1.5% | -8.4% | -13.1% | -37.3% | -14.5% | -17.1% | -2.5% | -6.5% |
| R&D / revenue | 13.4% | 14.6% | 16.8% | 15.2% | 17.7% | 16.4% | 13.5% | 13.2% | 10.8% | 8.5% |
| CapEx / revenue | 5.8% | 3.8% | 3.0% | 2.6% | 2.5% | 3.7% | 2.3% | 3.4% | 3.3% | 4.0% |
| Long-term debt / equity | 0.29x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | 28.4% | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | 41.2% | 19.9% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LIVN in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-07View SEC filing
Reconciliation checks needing review
3 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationreview2019-12-31
Difference 5753000 exceeds tolerance 2411797.000. Presentation or filing-vintage differences need review.
balance equationreview2018-12-31
Difference 3290000 exceeds tolerance 2549701.000. Presentation or filing-vintage differences need review.